ASTRAZENECA PLC ANNOUNCES FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA
Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing scheduleThis announcement contains inside information 14 November 2017 22:45 GMT FDA approval based on Phase III programme demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (